Titan Pharmaceuticals (FRA:TN70) YoY EBITDA Growth : 44.39% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Titan Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Titan Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 44.39%.

Titan Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2024 was €-1.14.

Titan Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Titan Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Titan Pharmaceuticals YoY EBITDA Growth Chart

Titan Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

80.69

79.36

45.93

15.03

38.05

Titan Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial															51.17	42.34	29.21	29.21	44.39

Titan Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Titan Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-8.737	-	-14.103)	/	\| -14.103 \|
=	38.05 %

Titan Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(-1.144	-	-2.057)	/	\| -2.057 \|
=	44.39 %

Titan Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Titan Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Titan Pharmaceuticals (FRA:TN70) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (FRA:TN70) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

TTNP:USA

Address

400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080

Website

https://www.titanpharm.com

Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.

Titan Pharmaceuticals (FRA:TN70) Headlines

No Headlines